Cardiometabolic Aspects of Polycystic Ovary Syndrome

The document explored the cardiometabolic risks associated with polycystic ovary syndrome (PCOS), focusing on the prevalence of metabolic syndrome (MetS) and the impact of omega-3 fatty acids on these risks. In a study of 168 women with PCOS and 883 controls, the prevalence of MetS was significantly higher in women with PCOS, with rates of 33% to 40% depending on the criteria used, compared to 10% to 13% in controls. Another study assessed endothelial function and arterial stiffness in 19 non-obese women with PCOS and 19 controls, finding that women with PCOS had significantly lower flow-mediated dilatation, indicating poorer endothelial function. The research suggested that PCOS is associated with increased cardiometabolic risk, which may be modifiable.